Antigen-binding constructs for target molecules

Engineered hinge regions in antigen-binding constructs address stability and aggregation issues, enhancing the efficacy of antigen targeting by preventing covalent cross-linking and optimizing clearance pathways.

JP7828375B2Active Publication Date: 2026-03-11IMAGINAB INC
View PDF 5 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-02-16
Publication Date
2026-03-11

AI Technical Summary

Technical Problem

Existing antigen-binding constructs, such as scFv fusion proteins, face challenges due to variations in CDR sequences and hinge region structures, which affect stability and clearance pathways, leading to aggregation and inefficient targeting of antigens.

Method used

The development of engineered hinge regions in antigen-binding constructs, including core and upper hinge sequences, with specific amino acid compositions that prevent covalent cross-linking and disulfide bond formation, ensuring stability and targeted antigen binding while minimizing aggregation.

Benefits of technology

The engineered hinge regions enhance the stability and clearance of antigen-binding constructs, reducing aggregation and improving their efficacy in targeting antigens like CD3, CD8, PSMA, and PSCA, with enhanced biodistribution and reduced kidney clearance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007828375000019
    Figure 0007828375000019
  • Figure 0007828375000020
    Figure 0007828375000020
  • Figure 0007828375000021
    Figure 0007828375000021
Patent Text Reader

Abstract

To provide hinge structures in antigen binding constructs (such as any scFv fusion proteins, such as minibodies), as well as the antigen binding constructs themselves, as well as methods for their use.SOLUTION: Antigen binding constructs that bind to desired targets are disclosed, for example, antibodies, including antibody fragments (such as scFv and minibodies) that bind to a target molecule, and have one or more of the disclosed hinges are described herein. Methods of use are described herein.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • IgG4 bispecific antibody modified to be sequence-symmetric

    JP2015513537A

  • IgG4 bispecific antibody modified to have an asymmetric sequence

    JP2015514684A

  • Recombinant immunoglobin preparations

    US4816567A

  • Single polypeptide chain binding molecules

    US4946778A

  • Use of novel markers of pluripotent stem cells

    WO2011096894A2